Laboratory Aide

Caris Life Sciences Stock is up 65% in Three Months, but its valuation multiple just got cheaper. Last updated Aug 24, 2026 Key Takeaways for Caris Life Sciences Stock as of August 2026. * Three-Month Run: Caris Life Sciences stock has climbed 65% since late May, closing at $26.27 on August 21 after a 45% year-over-year Q2 revenue beat flipped the growth story into a profitability story. * Street Split: 9 buys, 1 outperform, 3 holds among 12 analysts. * Model Upside: TIKR's mid-case valuation model targets $100 by December 2030, implying a 281% total return, or 36% annualized, from today's price. * Target Lag: The Street's mean target fell from $39 in September 2025 to $27 today, so this rally closed the valuation gap mostly through price appreciation rather than analysts raising numbers. Why Caris Life Sciences Stock Jumped 65% in Three Months. Caris Life Sciences (CAI) stock has climbed 65% since late May, closing at $26.27 on August 21 after a second-quarter report that turned a cash-burn growth story into a profitable one. The company posted revenue of $263.7 million on August 5, up 45% year over year, and narrowed its net loss to $0.6 million from $71.8 million a year earlier. That swing did the heavy lifting. Adjusted EBITDA rose to $55.7 million from $16.7 million a year ago, and Caris Life Sciences raised its full-year revenue guidance to a range of $1.03 billion to $1.04 billion, up from a prior $1 billion to $1.02 billion. Clinical case volume hit a record 59,200, up 18% year over year, driven by a sales force that grew past 300 reps. Vice Chairman and EVP Brian Brille put the inflection plainly on the Q2 earnings call: "Notably, this is our fifth consecutive quarter of positive adjusted EBITDA and positive free cash flow, and it provides us with valuable strategic flexibility for ongoing investment in our platform, new products and new channels such as MCED." That streak is what separated this print from prior quarters where growth came bundled with widening losses. Wall Street split on how far to take that story. BTIG lifted its target to $33 and Evercore ISI moved to $26 within two days of the report, while JPMorgan cut its target to $25 from $30 the same week. Caris Life Sciences stock kept climbing anyway, adding a further 6.88% on August 21 alone to close at $26.27, with no fresh company announcement that day. Even after the rally, Caris Life Sciences stock's NTM price to normalized earnings multiple has actually compressed, from 99 times on June 30 to 92x on August 21, the same three-month stretch in which the stock climbed 65%. That multiple was negative a year earlier and spiked above 719x in December 2025, when forward earnings estimates were still near zero, before settling in the 90 to 120 range as those estimates turned durably positive. The 65% move traded almost entirely on rising earnings estimates, not on investors paying more for the same dollar of forward profit. The 65% run reflects a business the market now believes can fund its own growth, not a name still chasing the multiple it had in May. Caris Life Sciences stock's earnings turn is the reason for the move. What comes next depends on whether the Street or the model has the longer horizon right. Caris Life Sciences Stock's Target Gap Has Nearly Closed. Wall Street's current read on Caris Life Sciences stock splits 9 buys, 1 outperform, and 3 holds across 12 analysts, with a mean target of $27 sitting just 3% above the $26.27 close. That gap has not always been this tight. The mean target stood at $39 in September 2025, fell to $38 by year end, then to $28 by June 2026 as the stock itself cratered to $17.82. evAnalysts were cutting numbers through the first half of the year almost as fast as the stock was falling. What changed since is the price, not the target: the mean has actually edged down further, from $28 to $27, even as Caris Life Sciences stock rallied 65% off its lows. Coverage grew from 8 analysts a year ago to 12 today, and holds appeared for the first time this cycle, growing to 3. The August run closed the valuation gap almost entirely through price catching up to a target range the Street had already set months earlier. TIKR's $100 Target Prices In Caris Life Sciences Stock's MCED Ramp. TIKR's mid-case model values Caris Life Sciences stock at $100 by December 2030, implying a 281% total return from the current price of $26.27, or 36% annualized over the next 4.4 years. That annualized rate sits well above what a mature diagnostics name typically offers investors, reflecting a model still treating Caris Life Sciences as an early-stage compounder rather than a business trading on this quarter's earnings alone. The gap between TIKR's $100 target and the Street's $27 mean target comes down to time horizon. Sell-side targets rarely price a stock more than 12 months out, while TIKR's model extends through the ramp of Caris Detect, the 58-cancer multi-cancer early detection test that launched in June and that management already flags as running ahead of lab capacity. Should You Invest in Caris Life Sciences, Inc.? The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question. Pull up Caris Life Sciences, Inc. stock and you'll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down. You can build a free watchlist to track Caris Life Sciences, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself. Looking for New Opportunities? * See what stocks billionaire investors are buying so you can follow the smart money. * Analyze stocks in as little as 5 minutes with TIKR's all-in-one, easy-to-use platform. * The more rocks you overturn... the more opportunities you'll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR. Disclaimer: Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or its content team, nor are they recommendations to buy or sell any stocks. TIKR create its content based on TIKR Terminal's investment data and analysts' estimates. Its analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing! Table of Contents * Key Takeaways for Caris Life Sciences Stock as of August 2026 * Why Caris Life Sciences Stock Jumped 65% in Three Months * Caris Life Sciences Stock's Target Gap Has Nearly Closed * TIKR's $100 Target Prices In Caris Life Sciences Stock's MCED Ramp * Should You Invest in Caris Life Sciences, Inc.? * Looking for New Opportunities? * Disclaimer: General Investing Earnings Updates Join thousands of investors worldwide who use TIKR to supercharge their investment analysis.

Caris Life Sciences has published research demonstrating a multimodal AI approach to predict late distant recurrence risk in hormone receptor-positive early breast cancer. The study appeared in Cancer Research Communications. The research, conducted with ECOG-ACRIN and NRG Oncology, integrated digitised pathology images with clinical data to generate risk predictions. The model was developed using specimens from 2,271 patients and validated in an independent cohort of 4,300 patients from the TAILORx study. In validation, the model identified a 10-year absolute distant recurrence risk difference of nearly 8% between high- and low-risk groups. It independently predicted late recurrence risk even after accounting for established clinical factors and the Oncotype DX Recurrence Score. The AI-based approach could offer a more accessible alternative to existing genomic assays by leveraging routinely available pathology slides, potentially helping oncologists identify patients at elevated risk and inform extended endocrine therapy decisions.

Caris Life Sciences announced it will offer in-house PTEN immunohistochemistry testing following recent FDA approval of a biomarker-guided therapy for metastatic prostate cancer. The testing helps identify patients with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive prostate cancer who are eligible for newly approved biomarker-guided therapy. Prostate cancer affects more than 300,000 new cases annually in the US. One in four patients with this type of metastatic prostate cancer have PTEN-deficient tumours, which are associated with faster progression and worse outcomes. The FDA approved capivasertib, combined with abiraterone and prednisone, for adults with PTEN-deficient tumours. Caris' testing will be performed in its CAP-accredited, CLIA-certified laboratories to deliver results efficiently for clinical decision-making. The company's molecular profiling portfolio includes MI Cancer Seek, Caris Assure, and Caris Detect, amongst other diagnostic solutions.